The American Cancer Society’s Report on the Status of Cancer Disparities in the United States examines disparities in cancer occurrence and outcomes, and analyzes the factors that contribute to these ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
Multidimensional intervention for patients with lung cancer incorporates rehabilitation, psychosocial support, nutrition guidance, health promotion, and safety surveillance. Multidimensional ...
Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.
The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...
Rural survivors were more likely to experience chronic pain than urban survivors, at rates of 43.0% and 33.5%, respectively. After controlling for several factors, the investigators found that rural ...
Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting. Researchers determined the BrECADD combination ...
In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.
TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.
Investigators sought to determine whether alcohol intake, particularly at higher frequency or greater quantity, was consistently associated with elevated risk for cancer.
Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback